Full Press Release Details
WALTHAM, Mass. , Dec. 4, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX ), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 11, 2023 , at 7:00 a.m. PT / 10:00 a.m. ET during the 65 th American Society of Hematology (ASH) Annual Meeting in San Diego, California .
The event will include new data for both the axatilimab and revumenib programs, and members of the Syndax management team will be joined by the following key opinion leaders:
• Daniel Wolff , M.D., Professor of Hematology, Department of Internal Medicine III of the University of Regensburg
• Eytan M. Stein , M.D., Chief, Program for Drug Development in Leukemia, Department of Medicine, Memorial Sloan Kettering Cancer Center
• Ghayas C. Issa , M.D., Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
• Joshua F. Zeidner , M.D., Associate Professor of Medicine, Chief, Leukemia Research, University of North Carolina , Lineberger Comprehensive Cancer Center
• Neerav N. Shukla , M.D., Chief, Pediatric Translational Medicine Service, Memorial Sloan Kettering Cancer Center
The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website or directly through the meeting link here .
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com for a limited time.
About Syndax
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn .
Syndax Contacts
Sharon Klahre Syndax Pharmaceuticals, Inc. [email protected] Tel 781.684.9827
SNDX-G